Commonwealth Equity Services
NRSN icon

Commonwealth Equity Services’s NeuroSense Therapeutics NRSN Stock Holding History

Commonwealth Equity Services’s Portfolio NRSN Stock Details NRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.4K Hold
22,775
– – ﹤0.01% 4378
2026
Q1 		$17.2K Hold
22,775
– – ﹤0.01% 4262
2025
Q4 		$17.5K Buy
22,775
+1,695
+8% +$1.78K ﹤0.01% 4248
2025
Q3 		$26K Hold
21,080
– – ﹤0.01% 4197
2025
Q2 		$40K Buy
21,080
+3,830
+22% +$5.55K ﹤0.01% 4180
2025
Q1 		$16K Buy
17,250
+1,000
+6% +$1.11K ﹤0.01% 4134
2024
Q4 		$20K Buy
16,250
+3,625
+29% +$4.17K ﹤0.01% 4041
2024
Q3 		$16K Buy
+12,625
New +$12K ﹤0.01% 4012

Other funds holding NRSN

YAG
Yorkville Advisors Global Mountainside, New Jersey $86.2M AUM 41.28% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Commonwealth Equity Services's NRSN Position: Q2 2026 in Review

Commonwealth Equity Services held its NeuroSense Therapeutics (NRSN) position steady in Q2 2026 at 22,775 shares worth $16.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4378.

Commonwealth Equity Services first reported a position in NRSN in Q3 2024 and has held it in 8 quarters since. The position peaked at $40K in Q2 2025. 4 funds tracked by Wall St. Rank hold NRSN as of Q2 2026.

  • Commonwealth Equity Services held 22,775 shares of NeuroSense Therapeutics worth $16.4K as of Q2 2026.
  • Commonwealth Equity Services left its NeuroSense Therapeutics share count unchanged in Q2 2026.
  • NeuroSense Therapeutics made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q2 2026, its #4378 holding.
  • Commonwealth Equity Services first reported a position in NeuroSense Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Commonwealth Equity Services's NeuroSense Therapeutics position peaked at $40K in Q2 2025.
  • 4 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q2 2026.

Based on Commonwealth Equity Services's 13F filing for Q2 2026, filed 29 Jul 2026.